CL2021001278A1 - Vesículas extracelulares modificadas y sus usos - Google Patents
Vesículas extracelulares modificadas y sus usosInfo
- Publication number
- CL2021001278A1 CL2021001278A1 CL2021001278A CL2021001278A CL2021001278A1 CL 2021001278 A1 CL2021001278 A1 CL 2021001278A1 CL 2021001278 A CL2021001278 A CL 2021001278A CL 2021001278 A CL2021001278 A CL 2021001278A CL 2021001278 A1 CL2021001278 A1 CL 2021001278A1
- Authority
- CL
- Chile
- Prior art keywords
- exosomes
- protein
- therapeutic
- luminal surface
- exosome
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 abstract 10
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción hace referencia a exosomas terapéuticos enriquecidos en proteínas que están presentes en la superficie luminal de los exosomas. La presente descripción proporciona métodos para fabricar exosomas enriquecidos en proteínas que están presentes en la superficie luminal de los exosomas, un método para asociar una proteína o péptido terapéutico a la superficie luminal de los exosomas y métodos de uso, por ejemplo, métodos de uso diagnóstico o terapéutico. Los métodos de fabricación implican generar exosomas modificados en la superficie luminal que incluyen una o más de la VE, por ejemplo, proteínas del exosoma en concentraciones mayores que las que se observan en exosomas de tipo salvaje, una modificación o un fragmento de la VE, por ejemplo, proteína del exosoma o una proteína de fusión de la VE, por ejemplo, proteína del exosoma y una carga útil, por ejemplo, una molécula activa desde un punto de vista biológico tal como un proteína terapéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/061679 WO2019099942A1 (en) | 2017-11-17 | 2018-11-16 | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
| US201962835430P | 2019-04-17 | 2019-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001278A1 true CL2021001278A1 (es) | 2022-03-11 |
Family
ID=70732111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001278A CL2021001278A1 (es) | 2018-11-16 | 2021-05-14 | Vesículas extracelulares modificadas y sus usos |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP3672614B1 (es) |
| JP (1) | JP2022513049A (es) |
| KR (1) | KR20210098473A (es) |
| CN (1) | CN113286603A (es) |
| AU (1) | AU2019378591A1 (es) |
| BR (1) | BR112021009231A2 (es) |
| CA (1) | CA3119720A1 (es) |
| CL (1) | CL2021001278A1 (es) |
| CY (1) | CY1124897T1 (es) |
| DK (1) | DK3672614T3 (es) |
| EA (1) | EA202191334A1 (es) |
| ES (1) | ES2907967T3 (es) |
| HR (1) | HRP20220020T1 (es) |
| HU (1) | HUE057300T2 (es) |
| IL (1) | IL283167A (es) |
| LT (1) | LT3672614T (es) |
| MA (1) | MA49971B1 (es) |
| MD (1) | MD3672614T2 (es) |
| MX (1) | MX2021005636A (es) |
| PH (1) | PH12021551088A1 (es) |
| PL (1) | PL3672614T3 (es) |
| PT (1) | PT3672614T (es) |
| RS (1) | RS62863B1 (es) |
| SG (1) | SG11202104956QA (es) |
| SI (1) | SI3672614T1 (es) |
| WO (1) | WO2020101740A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012540A (es) * | 2019-04-17 | 2022-01-18 | Codiak Biosciences Inc | Composiciones de exosomas y virus adenoasociados (aav). |
| EP3994158A1 (en) | 2019-07-03 | 2022-05-11 | Codiak BioSciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US20230193274A1 (en) | 2019-08-14 | 2023-06-22 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
| JP2022544290A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ， インコーポレイテッド | Ｋｒａｓを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞 |
| AU2020330133A1 (en) | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
| WO2021030776A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| WO2021062290A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ， インコーポレイテッド | 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用 |
| WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
| JP2022549328A (ja) | 2019-09-25 | 2022-11-24 | コディアック バイオサイエンシーズ， インコーポレイテッド | 細胞外小胞組成物 |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| JP2023517992A (ja) | 2020-03-12 | 2023-04-27 | インスティチュート フォー ベーシック サイエンス | ゲノム配列変異を有する細胞死滅誘導用組成物及び該組成物を用いた細胞死滅誘導方法 |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| US20240043494A1 (en) * | 2020-08-07 | 2024-02-08 | Amicus Therapeutics, Inc. | Vesicle Targeting Proteins And Uses Of Same |
| WO2022066934A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
| US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
| US20240167036A1 (en) * | 2021-02-17 | 2024-05-23 | Lonza Sales Ag | Extracellular vesicle-nlrp3 antagonist |
| KR20230157346A (ko) | 2021-02-17 | 2023-11-16 | 론자 세일즈 아게 | 세포외 소포체를 로딩하는 방법 |
| CN117120041A (zh) | 2021-04-01 | 2023-11-24 | 隆萨销售股份有限公司 | 胞外囊泡组合物 |
| CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
| CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
| WO2023229366A1 (en) * | 2022-05-24 | 2023-11-30 | Shiftbio Co., Ltd. | Surface-engineered extracellular vesicles and therapeutic uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR101640381B1 (ko) * | 2008-02-22 | 2016-07-18 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 입자 |
| FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| EP3164420A4 (en) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| US10501733B2 (en) * | 2015-02-27 | 2019-12-10 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| JP2019501179A (ja) * | 2015-12-30 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞由来ベシクルの向上された生成および単離のための方法 |
| US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
| EP3500244A4 (en) * | 2016-08-22 | 2020-05-13 | Codiak BioSciences, Inc. | METHOD FOR SUPPRESSING THE DELIVERY OF EXOSOMES TO LIVER AND SPLEEN |
| US20200025685A1 (en) * | 2016-12-15 | 2020-01-23 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
| SG11202001008RA (en) | 2017-08-25 | 2020-03-30 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
| CA3234784A1 (en) * | 2017-11-17 | 2019-05-23 | Lonza Sales Ag | Compositions of engineered exosomes and methods of loading luminal exosome payloads |
| MA53438A (fr) * | 2018-08-24 | 2021-09-15 | Codiak Biosciences Inc | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
-
2019
- 2019-05-22 JP JP2021526563A patent/JP2022513049A/ja active Pending
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/en active Active
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/en active Pending
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/zh active Pending
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko active Search and Examination
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-22 CA CA3119720A patent/CA3119720A1/en active Pending
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/en unknown
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro unknown
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4059510A1 (en) | 2022-09-21 |
| JP2022513049A (ja) | 2022-02-07 |
| WO2020101740A9 (en) | 2021-06-10 |
| CY1124897T1 (el) | 2023-01-05 |
| WO2020101740A1 (en) | 2020-05-22 |
| DK3672614T3 (da) | 2022-01-10 |
| HUE057300T2 (hu) | 2022-05-28 |
| CA3119720A1 (en) | 2020-05-22 |
| PH12021551088A1 (en) | 2022-01-03 |
| IL283167A (en) | 2021-06-30 |
| CN113286603A (zh) | 2021-08-20 |
| MD3672614T2 (ro) | 2022-04-30 |
| EP3672614A1 (en) | 2020-07-01 |
| AU2019378591A1 (en) | 2021-06-17 |
| SG11202104956QA (en) | 2021-06-29 |
| PL3672614T3 (pl) | 2022-03-07 |
| EA202191334A1 (ru) | 2022-02-10 |
| SI3672614T1 (sl) | 2022-04-29 |
| KR20210098473A (ko) | 2021-08-10 |
| HRP20220020T1 (hr) | 2022-04-01 |
| PT3672614T (pt) | 2022-02-11 |
| MX2021005636A (es) | 2021-07-06 |
| EP3672614B1 (en) | 2021-10-06 |
| TW202038993A (zh) | 2020-11-01 |
| LT3672614T (lt) | 2022-04-11 |
| MA49971B1 (fr) | 2022-01-31 |
| BR112021009231A2 (pt) | 2021-08-10 |
| MA49971A (fr) | 2020-07-01 |
| ES2907967T3 (es) | 2022-04-27 |
| RS62863B1 (sr) | 2022-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001278A1 (es) | Vesículas extracelulares modificadas y sus usos | |
| AR115159A1 (es) | Vesículas extracelulares modificadas y usos de las mismas | |
| CL2020000428A1 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana. | |
| MX2020008455A (es) | Variantes de il-15 y usos de las mismas. | |
| BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
| PE20200303A1 (es) | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| CL2018003438A1 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos. | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
| AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| DOP2020000040A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| PE20191711A1 (es) | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer | |
| NI202000014A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| CL2020002965A1 (es) | Anticuerpos anti-cd63, conjugados y usos de estos | |
| CO2022002808A2 (es) | Proteínas de fusión nkg2d y sus usos | |
| DOP2016000079A (es) | Glicoproteinas recombinantes y sus usos | |
| CO2021003136A2 (es) | Terapias de combinación | |
| BR112021011595A2 (pt) | Proteína biespecífica | |
| AR110871A1 (es) | Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas | |
| UY37276A (es) | Dispositivo para la esterilizacion de bolsas flexibles mediante irradiacion por haz de electrones y procedimiento de esterilizacion de las mismas | |
| CU20160194A7 (es) | Composición vacunal que comprende un mutante de la interleucina-15 humana |